Lucid Diagnostics IncLUCD
▼ NegativeCapitalrelevance
Q2 revenue missed estimates and EPS was negative, though revenue grew YoY.
Impact on stocks 1
Biotech & Genomic Medicine
Lucid Diagnostics IncLucid Diagnostics reported second quarter 2026 financial results with non-GAAP EPS of negative $0.06, missing estimates by $0.01, and revenue of $1.47 million, up 26.7% year over year but missing expectations by $0.46 million. The company processed 2,770 EsoGuard tests during the quarter. Lucid had cash and cash equivalents of $33.4 million as of June 30, 2026, compared to $34.7 million as of December 31, 2025.
Lucid Diagnostics IncQ2 revenue missed estimates and EPS was negative, though revenue grew YoY.